Pure Transplant Solutions

Pure Transplant Solutions, L.L.C., a wholly owned subsidiary of Pure Protein, L.L.C. uses the power of our soluble HLA production technology to create tools specifically for organ and tissue transplant and for transfusion medicine.

Sequence Based Typing (SBT)

Pure Transplant Solutions has a state-of-the-art ASHI CLIA accredited laboratory offering both SBT services and SBT kits. <more>

Pure Transplant Solutions Datasheet

The Role of HLAs in Transplantation Medicine and Autoimmunity Research

Class I and II HLA molecules are termed major histocompatibility complex (MHC) molecules because they represent the primary barriers to the transplantation of organs (heart, kidney, liver, lung) and bone marrow. Matching of donor and recipient for their HLA Class I and Class II is a prerequisite to successful transplantation. Because the population is so diverse at the HLA complex, the matching of transplant donors and recipients is quite challenging.

In addition to organ and tissue transplant medicine, another active area of work is in Transfusion Medicine. Blood centers have traditionally focused on typing red blood cell antigens using the ABO and Rh systems. Red blood cell antigens that are recognized as non-self can lead to severe immunological responses, and even death. More recently, the most common transfusion-related death has become Transfusion Related Acute Lung Injury (TRALI), which is still not fully characterized. TRALI is thought to be caused not by antigens within donated blood but by anti-HLA antibodies, such as from females who have been through a pregnancy or donors who have previously received a transfusion themselves.

Pure Transplant Solutions’ HLA molecules can be used as a research tool to unravel the mechanisms of transplant and transfusion immunology as well as autoimmune disease. Our sHLA Class I and II molecules may additionally be used to diagnose autoimmune disease and potentially to modulate or alleviate particular autoimmune diseases.